Abstract
The purpose of this study was to investigate the feasibility of postoperative concomitant chemoradiotherapy （CRT） with cisplatin （CDDP）, and to compare the prognosis in three groups: without postoperative therapy （S-only）, with radiotherapy （RT） alone （S＋RT）, and with CRT （S＋CRT）, in oral squamous cell carcinoma （OSCC） patients at high risk of recurrence （Extranodal Extension （ENE） （n＝116））.
There were 39 patients （84.8%） in the S＋CRT group who were administered a cumulative cisplatin dose of more than 200mg/㎡ The 3-year cumulative LRC rates for the S-only, S＋RT, and S＋CRT groups were 35.4%, 53.6%, and 68.9%, respectively. The 3-year cumulative OS rates for the S-only, S＋RT, and S＋CRT groups were 25.1%, 59.2%, and 43.8%, respectively. These results suggest that the addition of concomitant cisplatin to postoperative RT improved LRC in OSCC patients. There may be no benefit from the addition of concomitant CDDP to postoperative RT for DM and OS rates in OSCC patients.
We discuss the indication of surgery, the selection of neck dissection, and postoperative chemoradiotherapy in view of lymph node metastasis.
